Early Gastric Cancer in the Spanish EURECCA Registry

NCT07781319 | Completed

• 2 other identifiers: PT-EGC-2026-089CEIm 2026.089-50
• Study Type: observational
• Target: 600
• Locations: 0 countries
• Sites: N/A

Brief Summary

Early gastric cancer (EGC) is increasingly diagnosed in Western countries; however, important differences remain with Eastern populations regarding staging accuracy, treatment strategies, and the risk of lymph node metastasis. While endoscopic resection is the standard treatment for selected EGC in Asia based on well-established criteria, the applicability of these criteria to Western populations remains uncertain because of differences in epidemiology, clinical practice, and pathological characteristics. This multicenter retrospective cohort study, based on the Spanish EURECCA Registry, aims to evaluate the concordance between clinical and pathological staging, determine the real incidence and predictors of lymph node metastasis in patients with pathological T1 gastric cancer, assess the applicability of standard and expanded Asian endoscopic resection criteria in a Western cohort, and analyze long-term oncological outcomes, including recurrence and overall survival.

Conditions

Early Gastric Cancer; Gastric Adenocarcinoma

Keywords

Early Gastric Cancer; Gastric Adenocarcinoma; Clinical Staging; Pathological Staging; Lymph Node Metastasis; Western Population; Multicenter Registry

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants With Concordant Clinical and Pathological Staging

  Percentage of participants in whom preoperative clinical staging (cT and cN) was concordant with final pathological staging (pT and pN). Concordance will be assessed by comparing clinical and pathological tumor depth and lymph node status.

  Baseline

• Lymph node metastasis

  Percentage of participants with pathological lymph node metastasis (pN+) among patients with pathological T1 gastric adenocarcinoma. Lymph node status will be determined from the definitive pathological examination of the surgical specimen.

  Baseline

Secondary Outcomes (7)

• Applicability of Standard Asian Endoscopic Resection Criteria

  Baseline

• Applicability of Expanded Asian Endoscopic Resection Criteria

  Baseline

• Overall Survival

  Up to 5 years after surgery

• Disease-Free Survival

  Up to 5 years after surgery

• Percentage of Participants With Tumor Recurrence

  Up to 5 years after surgery

Study Arms (1)

Early Gastric Cancer Cohort

Patients with surgically treated early gastric adenocarcinoma (pathological T1) included in the multicenter Spanish EURECCA Registry between January 2014 and December 2022. Patients underwent curative-intent gastrectomy with lymph node dissection according to routine clinical practice at participating centers. Clinical, pathological, treatment, and follow-up data were retrospectively analyzed.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients with a preoperative clinical diagnosis of early gastric cancer (cT1) who underwent curative-intent gastrectomy with lymph node dissection at participating centers of the Spanish EURECCA Registry between January 2014 and December 2022. The cohort includes patients with histologically confirmed gastric adenocarcinoma and complete clinicopathological and follow-up data available for analysis. This population was selected to evaluate the accuracy of preoperative clinical staging and to investigate the pathological characteristics and oncological outcomes of early gastric cancer in a Western multicenter cohort.

You may qualify if:

• Adults (≥18 years of age)
• Clinical diagnosis of early gastric cancer (cT1) before surgery.
• Curative-intent gastrectomy with lymph node dissection performed between
• January 2014 and December 2022.
• Histologically confirmed gastric adenocarcinoma.
• Availability of complete preoperative clinical staging, pathological findings, and follow-up data required for the study analyses.

You may not qualify if:

• Receipt of neoadjuvant therapy before surgery.
• Incomplete pathological data precluding accurate tumor staging or lymph node assessment.
• Non-adenocarcinoma gastric tumors.

Sponsors & Collaborators

• Corporacion Parc Tauli: lead
• Spanish EURECCA Group for Esophagogastric Surgery (GEECEG): collaborator

MeSH Terms

Conditions

Stomach Neoplasms; Lymphatic Metastasis

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: August 16, 2026
• First Posted: August 24, 2026
• Study Start: January 1, 2014
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: August 24, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share